Eric Langer
Eric Langer is a member of Pharmaceutical TEchnology's editorial advisory board.
Mr. Eric Langer
President and Managing Partner
BioPlan Associates
Eric Langer is president and managing partner of BioPlan Associates (Rockville, MD), a biotechnology and life-sciences marketing company that provides information, market research, pricing, and market analysis to biotechnology and healthcare organizations. Eric cofounded BioPlan Associates in 1989.
He has more than 20 years of experience in biotechnology and life-sciences international marketing, management, market assessment, and publishing, which includes senior management and marketing positions at biopharmaceutical supply companies. He has launched and managed marketing programs for product lines ranging from $500,000 to $500 million.
Eric has published, edited, and authored numerous books, reports, and major studies on a variety of topics including: advances in biopharmaceutical technology in China, advances in large-scale biopharmaceutical manufacturing, biopharmaceuticals in the US market, cell-culture, media, sera, tissue engineering, stem cells, diagnostic products, blood products, genetics, DNA/PCR purification, and blood components. He also lectures extensively on pricing and channel-management topics and teaches at Johns Hopkins University and American University.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
INTERPHEX 2025: Use of Walk-In Chambers for Bio/Pharma Development and Manufacturing
April 2nd 2025Sitting down with the PharmTech Group at INTERPHEX 2025, Christopher Murphy, director of Global Business Development and Service Customer Support at Environmental Specialties, discusses the design and critical role of walk-in chambers in the bio/pharmaceutical industry.
